Molecular Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
¼¼°è ºÐÀÚÁø´Ü ½ÃÀå ±Ô¸ð´Â 2025³â¿¡ 252¾ï ´Þ·¯, 2025³â-2032³âÀÇ ¿¹Ãø ±â°£¿¡ 8.1%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÏ¿© 2032³â¿¡´Â 434¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.
ºÐÀÚÁø´ÜÀº À¯ÀüüÀ̳ª ÇÁ·ÎÅ×¿È ÁßÀÇ »ý¹°ÇÐÀû ¸¶Ä¿¸¦ ºÐ¼®ÇÏ¿© Áúº´ÀÇ Áø´Ü°ú ¸ð´ÏÅ͸µ, À§ÇèÀÇ °ËÃâ, °³º° ȯÀÚ¿¡°Ô ÃÖÀûÀÇ Ä¡·á¹ýÀÇ °áÁ¤ µîÀ» ½Ç½ÃÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ ºÐ¾ß´Â Á¤È®¼º, ½Å¼Ó¼º ¹× Ä¡·áÀÇ °³º°È °¡´É¼ºÀ¸·Î ÀÎÇØ ÀÓ»ó¿¡¼ Á¡Á¡ ´õ ÇʼöÀûÀÔ´Ï´Ù. ºÐÀÚÁø´Ü ½ÃÀåÀº PCR, NGS, ¸¶ÀÌÅ©·Î¾î·¹ÀÌ, Á¦ÀÚ¸® ºÎÇÕ¹ý°ú °°Àº ±â¼úÀ» Æ÷ÇÔÇÏ¿© º´¿ø, Áø´Ü¿¬±¸¼Ò, ¿¬±¸±â°ü, ÀçÅÃÀÇ·áÀÇ ÇöÀå¿¡¼ ÀÌ¿ëµÇ°í ÀÖ½À´Ï´Ù. ½ÃÀå È®´ëÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ´Â °ÍÀº Áúº´ÀÇ Á¶±â ¹ß°ß¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, °¨¿°ÁõÀ̳ª ¸¸¼º ÁúȯÀÇ À¯Çà Áõ°¡, ºÐÀÚ ±â¼úÀÇ Áö¼ÓÀûÀÎ Çõ½ÅÀÔ´Ï´Ù.
½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
¼¼°èÀÇ ºÐÀÚÁø´Ü ½ÃÀåÀº COVID-19, HIV, °£¿°, °áÇÙ°ú °°Àº °¨¿° ºÎ´ã Áõ°¡¿Í °°Àº ¸î °¡Áö Áß¿äÇÑ ¿äÀο¡ ÀÇÇØ ÃßÁøµÇ°í ÀÖ½À´Ï´Ù. °Ô´Ù°¡, °³ÀÎÈµÈ ÀÇ·á ¹× Ç¥Àû Ä¡·á°¡ Á߽õǰí Á¤È®ÇÑ ºÐÀÚ °Ë»ç°¡ ÇÊ¿äÇÕ´Ï´Ù. Á¾¾çÇп¡¼ µ¿¹ÝÁø´ÜÀÇ º¸±Þ°ú ÇÔ²² POC(Point of Care) Áø´ÜÀÇ »ç¿ëÀÌ Áõ°¡Çϰí ÀÖ´Ù´Â °Íµµ ¼ö¿ä¸¦ ´õ¿í ³ôÀ̰í ÀÖ½À´Ï´Ù. ÀÚµ¿È, ½Ç½Ã°£ PCR, Â÷¼¼´ë ½ÃÄö½ÌÀÇ ±â¼úÀû Áøº¸·Î Áø´Ü È¿À²¼º, ¼Óµµ ¹× °¨µµ°¡ Çâ»óµÇ¾î °Ç° °ü¸® ½Ã½ºÅÛ Àü¹Ý ½ÃÀå µµÀÔÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù.
½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
À¯¸ÁÇÑ ¼ºÀå¿¡µµ ºÒ±¸ÇÏ°í ºÐÀÚÁø´Ü ½ÃÀåÀº ƯÈ÷ Àú¼Òµæ ¹× Áß»êÃþ ±¹°¡¿¡¼ Àåºñ ¹× °Ë»ç ºñ¿ëÀÌ ³ôÀº µîÀÇ °úÁ¦¿¡ Á÷¸éÇϰí ÀÖ½À´Ï´Ù. ƯÈ÷ ½Å±Ô Áø´Ü Åø¿¡ ´ëÇØ¼´Â »óȯÀÇ Á¦ÇÑÀÌ ÀÖ¾î, Á¢±Ù¼ºÀÌ Á¦Çѵǰí ÀÖ½À´Ï´Ù. ±ÔÁ¦ÀÇ º¹À⼺°ú ½Ã°£ÀÌ ¸¹ÀÌ °É¸®´Â ½ÂÀÎ ÇÁ·Î¼¼½ºµµ ±â¼ú Çõ½Å°ú ½ÃÀå ÁøÀÔÀÇ À庮ÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¦ÇÑµÈ ÀÚ¿ø ȯ°æ¿¡¼ ¼÷·ÃµÈ °Ë»ç Àü¹®°¡ÀÇ ºÎÁ·°ú ÀÎÇÁ¶óÀÇ Á¦¾àÀº °í±Þ ºÐÀÚÁø´ÜÀÇ Ã¤ÅÃÀ» ¹æÇØÇÕ´Ï´Ù.
½ÃÀå ±âȸ
ºÐÀÚÁø´Ü ½ÃÀåÀº Á¾¾çÇÐ, À¯ÀüÀÚ°Ë»ç, ¾à¸®À¯ÀüüÇÐ, °¨¿°Áõ °ü¸®¿¡ ÀÖ¾î¼ÀÇ ¿ëµµÀÇ È®´ë¿¡ ÀÇÇØ Å« ¼ºÀå ±âȸ¸¦ °¡Á®¿À°í ÀÖ½À´Ï´Ù. µ¥ÀÌÅÍ ºÐ¼®À» À§ÇÑ ÀΰøÁö´É°ú ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½ºÀÇ ÅëÇÕÀº Áø´Ü Àü¸ÁÀ» ¹Ù²Ù°í ÀÖ½À´Ï´Ù. ¿¬±¸¿¡ ´ëÇÑ ÅõÀÚ¿Í ¹Î°£ Çù·Â Áõ°¡´Â ÷´Ü ºÐÀÚ °Ë»çÀÇ Çõ½Å°ú »ó¾÷ȸ¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Áúº´ÀÇ Á¶±â ¹ß°ß¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡¿Í ƯÈ÷ ½ÅÈï ½ÃÀåÀÇ ÀÇ·á ÁöÃâ Áõ°¡´Â ½ÃÀå È®´ëÀÇ »õ·Î¿î ±æÀ» ¿ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. °Ô´Ù°¡, Æ÷ÀÎÆ® ¿Àºê ÄÉ¾î °Ë»ç¿ëÀÇ ÈÞ´ë¿ëÀ¸·Î »ç¿ëÇϱ⠽¬¿î ºÐÀÚÁø´Ü ŶÀÇ °³¹ß¿¡ ÀÇÇØ µµ½Ã¿¡¼µµ ¿ø°ÝÁö¿¡¼µµ ȯÀÚ Äɾ Çõ¸íÀÌ ÀϾ·Á°í Çϰí ÀÖ½À´Ï´Ù.
º» º¸°í¼¿¡¼´Â ¼¼°èÀÇ ºÐÀÚÁø´Ü ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, Á¦Ç° À¯Çüº°, Áúȯ ¿µ¿ªº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº° µ¿Çâ ¹× ½ÃÀå ÁøÃâ±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀÇ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù.
¸ñÂ÷
Á¦1Àå ÁÖ¿ä ¿ä¾à
Á¦2Àå ½ÃÀå °³¿ä
½ÃÀåÀÇ ¹üÀ§¿Í Á¤ÀÇ
¹ë·ùüÀÎ ºÐ¼®
°Å½Ã°æÁ¦ ¿äÀÎ
¿¹Ãø ¿äÀÎ- °ü·Ã¼º°ú ¿µÇâ
COVID-19ÀÇ ¿µÇâ Æò°¡
PESTLE ºÐ¼®
Porter's Five Forces ºÐ¼®
ÁöÁ¤ÇÐÀû ±äÀå : ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâ
±ÔÁ¦¿Í ±â¼úÀÇ »óȲ
Á¦3Àå ½ÃÀå ¿ªÇÐ
¼ºÀå ÃËÁø¿äÀÎ
¾ïÁ¦¿äÀÎ
±âȸ
µ¿Çâ
Á¦4Àå °¡°Ý µ¿Ç⠺м®, 2019³â-2032³â
Áö¿ªº° °¡°Ý ºÐ¼®
ºÎ¹®º° °¡°Ý
°¡°Ý ¿µÇâ¿äÀÎ
Á¦5Àå ¼¼°èÀÇ ºÐÀÚÁø´Ü ½ÃÀå Àü¸Á : ½ÇÀû(2019³â-2024³â) ¹× ¿¹Ãø(2025³â-2032³â)
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
¼¼°èÀÇ ºÐÀÚÁø´Ü ½ÃÀå Àü¸Á : Á¦Ç° À¯Çüº°
¼Ò°³/ÁÖ¿ä Á¶»ç °á°ú
½ÃÀå ±Ô¸ð ÃßÀÌ ºÐ¼®, Á¦Ç° À¯Çüº°, 2019³â-2024³â
ÇöÀç ½ÃÀå ±Ô¸ð ¿¹Ãø, Á¦Ç° À¯Çüº°, 2025³â-2032³â
±â±â
ÁßÇÕÈ¿¼Ò ¿¬¼â¹ÝÀÀ(PCR) ½Ã½ºÅÛ
Á¦ÀÚ¸® ºÎÇÕ¹ý(In-Situ Hybridization) ¹× Çü±¤ Á¦ÀÚ¸® ºÎÇÕ¹ý(FISH) ½Ã½ºÅÛ
DNA ½ÃÄö½Ì ¹× Â÷¼¼´ë ½ÃÄö½Ì Ç÷§Æû
¸¶ÀÌÅ©·Î¾î·¹ÀÌ
½Ã¾à
Ç×ü
DNA ÅÛÇø´
DNA ÁßÇÕÈ¿¼Ò
Oligonucleotide Primers
Deoxyribonucleotide Triphosphate(dNTP)
¹öÆÛ
ºÐ¼® ŰƮ
¼Ò¸ðǰ
½ÃÀå ¸Å·Â ºÐ¼® : Á¦Ç° À¯Çüº°
¼¼°èÀÇ ºÐÀÚÁø´Ü ½ÃÀå Àü¸Á : Áúȯ ¿µ¿ªº°
¼Ò°³/ÁÖ¿ä Á¶»ç °á°ú
½ÃÀå ±Ô¸ð ÃßÀÌ ºÐ¼®, Áúȯ ¿µ¿ªº°, 2019³â-2024³â
ÇöÀç ½ÃÀå ±Ô¸ð ¿¹Ãø, Áúȯ ¿µ¿ªº°, 2025³â-2032³â
°¨¿°Áõ
´ç´¢º´
½ÉÀ庴ÇÐ
Á¾¾çÇÐ
½ÅÀåÇÐ
ÀÚ°¡¸é¿ªÁúȯ
ÇǺΰú
»óó Äɾî
±âŸ
½ÃÀå ¸Å·Â ºÐ¼® : Áúº´ ¿µ¿ªº°
¼¼°èÀÇ ºÐÀÚÁø´Ü ½ÃÀå Àü¸Á : ÃÖÁ¾ ¿ëµµº°
¼Ò°³/ÁÖ¿ä Á¶»ç °á°ú
½ÃÀå ±Ô¸ð ÃßÀÌ ºÐ¼®, ÃÖÁ¾ ¿ëµµº°, 2019³â-2024³â
ÇöÀç ½ÃÀå ±Ô¸ð ¿¹Ãø, ÃÖÁ¾ ¿ëµµº°, 2025³â-2032³â
º´¿ø ¹× Áø·á¼Ò
Áø´Ü ½ÇÇè½Ç
Çмú¿¬±¸±â°ü
¹ÙÀÌ¿ÀÀǾàǰ±â¾÷
½ÃÀå ¸Å·Â ºÐ¼® : ÃÖÁ¾ ¿ëµµº°
Á¦6Àå ¼¼°èÀÇ ºÐÀÚÁø´Ü ½ÃÀå Àü¸Á : Áö¿ªº°
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
½ÃÀå ±Ô¸ð ÃßÀÌ ºÐ¼®, Áö¿ªº°, 2019³â-2024³â
ÇöÀç ½ÃÀå ±Ô¸ð ¿¹Ãø, Áö¿ªº°, 2025³â-2032³â
ºÏ¹Ì
À¯·´
µ¿¾Æ½Ã¾Æ
³²¾Æ½Ã¾Æ¿Í ¿À¼¼¾Æ´Ï¾Æ
¶óƾ¾Æ¸Þ¸®Ä«
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
½ÃÀå ¸Å·Â ºÐ¼® : Áö¿ªº°
Á¦7Àå ºÏ¹ÌÀÇ ºÐÀÚÁø´Ü ½ÃÀå Àü¸Á : ½ÇÀû(2019³â-2024³â) ¹× ¿¹Ãø(2025³â-2032³â)
Á¦8Àå À¯·´ÀÇ ºÐÀÚÁø´Ü ½ÃÀå Àü¸Á : ½ÇÀû(2019³â-2024³â) ¹× ¿¹Ãø(2025³â-2032³â)
Á¦9Àå µ¿¾Æ½Ã¾ÆÀÇ ºÐÀÚÁø´Ü ½ÃÀå Àü¸Á : ½ÇÀû(2019³â-2024³â) ¹× ¿¹Ãø(2025³â-2032³â)
Á¦10Àå ³²¾Æ½Ã¾Æ ¹× ¿À¼¼¾Æ´Ï¾ÆÀÇ ºÐÀÚÁø´Ü ½ÃÀå Àü¸Á : ½ÇÀû(2019³â-2024³â) ¹× ¿¹Ãø(2025³â-2032³â)
Á¦11Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ ºÐÀÚÁø´Ü ½ÃÀå Àü¸Á : ½ÇÀû(2019³â-2024³â) ¹× ¿¹Ãø(2025³â-2032³â)
Á¦12Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ºÐÀÚÁø´Ü ½ÃÀå Àü¸Á : ½ÇÀû(2019³â-2024³â) ¹× ¿¹Ãø(2025³â-2032³â)
Á¦13Àå °æÀï ±¸µµ
½ÃÀå Á¡À¯À² ºÐ¼®, 2025³â
½ÃÀå ±¸Á¶
±â¾÷ ÇÁ·ÎÆÄÀÏ
Becton, Dickinson and Company
Bio-Rad Laboratories In
Merck KgaA
Thermo Fisher Scientific Inc
Agilent Technologies, Inc.
F. Hoffman-La Roche Ltd.
Illumina, Inc.
Qiagen NV
Hologic Inc.
Siemens Healthineers AG
Seegene, Inc.
DiaSorin SpA
Grifols, SA
bioMerieux
QuidelOrtho Corporation
Á¦14Àå ºÎ·Ï
SHW
Persistence Market Research has recently released a comprehensive report on the worldwide market for molecular diagnostics. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure.
Key Insights:
Molecular Diagnostics Market Size (2025E): USD 25.2 Billion
Projected Market Value (2032F): USD 43.4 Billion
Global Market Growth Rate (CAGR 2025 to 2032): 8.1%
Molecular Diagnostics Market - Report Scope:
Molecular diagnostics involves the analysis of biological markers in the genome and proteome to diagnose and monitor disease, detect risk, and decide which therapies will work best for individual patients. This segment has become increasingly essential in clinical practice due to its accuracy, speed, and potential for personalization of treatment. The molecular diagnostics market serves hospitals, diagnostic laboratories, research institutes, and homecare settings, encompassing technologies like PCR, NGS, microarrays, and in situ hybridization. Market expansion is being driven by rising demand for early disease detection, increased prevalence of infectious and chronic diseases, and continuous innovations in molecular technologies.
Market Growth Drivers:
The global molecular diagnostics market is propelled by several key factors, including the rising burden of infectious diseases such as COVID-19, HIV, hepatitis, and tuberculosis. Additionally, the growing emphasis on personalized medicine and targeted therapies necessitates accurate molecular testing. The increasing use of point-of-care diagnostics, along with the proliferation of companion diagnostics in oncology, further enhances the demand. Technological advancements in automation, real-time PCR, and next-generation sequencing are improving diagnostic efficiency, speed, and sensitivity, thereby expanding market adoption across healthcare systems.
Market Restraints:
Despite promising growth, the molecular diagnostics market faces certain challenges, such as high cost of instruments and tests, especially in low- and middle-income countries. Reimbursement limitations, particularly for novel diagnostic tools, restrict accessibility. Regulatory complexities and time-consuming approval processes also act as barriers to innovation and market entry. Furthermore, the shortage of skilled laboratory professionals and infrastructure constraints in resource-limited settings hinder the adoption of advanced molecular diagnostics.
Market Opportunities:
The molecular diagnostics market presents significant growth opportunities fueled by expanding applications in oncology, genetic testing, pharmacogenomics, and infectious disease management. The integration of artificial intelligence and bioinformatics for data analysis is transforming the diagnostic landscape. Increasing investments in research and public-private collaborations are promoting innovation and commercialization of cutting-edge molecular tests. Growing awareness about early disease detection and rising healthcare spending, especially in emerging markets, are expected to unlock new avenues for market expansion. Additionally, the development of portable and easy-to-use molecular diagnostic kits for point-of-care testing is set to revolutionize patient care in both urban and remote areas.
Key Questions Answered in the Report:
What are the primary factors driving the growth of the molecular diagnostics market globally?
Which technologies and applications are most widely adopted in clinical molecular diagnostics?
How are emerging technologies like NGS and AI impacting the competitive landscape?
Who are the leading companies in the molecular diagnostics market, and what strategies are they using to stay competitive?
What are the key trends and future outlook for the global molecular diagnostics market?
Competitive Intelligence and Business Strategy:
These companies focus on expanding their test portfolios, developing multiplex and syndromic testing panels, and enhancing automation and throughput of diagnostic systems. Collaborations with biotechnology firms, diagnostic labs, and healthcare institutions drive access and adoption. Furthermore, companies are prioritizing regulatory approvals, market expansion in developing economies, and customer-centric strategies to reinforce their global presence.
Key Companies Profiled:
Becton, Dickinson and Company
Bio-Rad Laboratories In
Merck KgaA
Thermo Fisher Scientific Inc
Agilent Technologies, Inc.
F. Hoffman - La Roche Ltd.
Illumina, Inc.
Qiagen N.V.
Hologic Inc.
Siemens Healthineers AG
Seegene, Inc.
DiaSorin S.p.A
Grifols, S.A.
bioMerieux
QuidelOrtho Corporation
RapidBio
Abbott Laboratories
Danaher Corporation
Molecular Diagnostics Market Research Segmentation:
By Product Type:
Instruments
* Polymerase Chain Reaction (PCR) Systems
* Hybridization (In-Situ Hybridization & Fish) Systems
* DNA Sequencing and Next-Generation Sequencing Platforms
* Microarrays
Reagent
* Antibodies
* DNA Template
* DNA Polymerase
* Oligonucleotide Primers
* Deoxyribonucleotide Triphosphate (dNTPs)
* Buffer
Assay Kits
Consumables
By Disease Area:
Infectious Disease
Diabetes
Cardiology
Oncology
Nephrology
Autoimmune Disease
Dermatology
Wound Care
Others
By End-use:
Hospitals & Clinics
Diagnostics Laboratories
Academic and Research Institutes
Biopharmaceutical Companies
By Region:
North America
Europe
East Asia
South Asia & Oceania
Latin America
Middle East & Africa
Table of Contents
1. Executive Summary
1.1. Global Molecular Diagnostics Market Snapshot 2025 and 2032
1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
1.3. Key Market Trends
1.4. Industry Developments and Key Market Events
1.5. Demand Side and Supply Side Analysis
1.6. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definitions
2.2. Value Chain Analysis
2.3. Macro-Economic Factors
2.3.1. Global GDP Outlook
2.3.2. Global GDP Outlook
2.3.3. Global economic Growth Forecast
2.3.4. Global Urbanization Growth
2.3.5. Other Macro-economic Factors
2.4. Forecast Factors - Relevance and Impact
2.5. COVID-19 Impact Assessment
2.6. PESTLE Analysis
2.7. Porter's Five Forces Analysis
2.8. Geopolitical Tensions: Market Impact
2.9. Regulatory and Technology Landscape
3. Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities
3.4. Trends
4. Price Trend Analysis, 2019-2032
4.1. Region-wise Price Analysis
4.2. Price by Segments
4.3. Price Impact Factors
5. Global Molecular Diagnostics Market Outlook: Historical (2019-2024) and Forecast (2025-2032)
5.1. Key Highlights
5.2. Global Molecular Diagnostics Market Outlook: Product Type
5.2.1. Introduction/Key Findings
5.2.2. Historical Market Size (US$ Bn) Analysis by Product Type, 2019-2024
5.2.3. Current Market Size (US$ Bn) Forecast, by Product Type, 2025-2032
5.2.3.1. Instruments
5.2.3.1.1. Polymerase Chain Reaction (PCR) Systems
5.2.3.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
5.2.3.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
5.2.3.1.4. Microarrays
5.2.3.2. Reagent
5.2.3.2.1. Antibodies
5.2.3.2.2. DNA Template
5.2.3.2.3. DNA Polymerase
5.2.3.2.4. Oligonucleotide Primers
5.2.3.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
5.2.3.2.6. Buffer
5.2.3.3. Assay Kits
5.2.3.4. Consumables
5.2.4. Market Attractiveness Analysis: Product Type
5.3. Global Molecular Diagnostics Market Outlook: Disease Area
5.3.1. Introduction/Key Findings
5.3.2. Historical Market Size (US$ Bn) Analysis by Disease Area, 2019-2024
5.3.3. Current Market Size (US$ Bn) Forecast, by Disease Area, 2025-2032
5.3.3.1. Infectious Disease
5.3.3.2. Diabetes
5.3.3.3. Cardiology
5.3.3.4. Oncology
5.3.3.5. Nephrology
5.3.3.6. Autoimmune Disease
5.3.3.7. Dermatology
5.3.3.8. Wound Care
5.3.3.9. Others
5.3.4. Market Attractiveness Analysis: Disease Area
5.4. Global Molecular Diagnostics Market Outlook: End-use
5.4.1. Introduction/Key Findings
5.4.2. Historical Market Size (US$ Bn) Analysis by End-use, 2019-2024
5.4.3. Current Market Size (US$ Bn) Forecast, by End-use, 2025-2032
5.4.3.1. Hospitals & Clinics
5.4.3.2. Diagnostics Laboratories
5.4.3.3. Academic and Research Institutes
5.4.3.4. Biopharmaceutical Companies
5.4.4. Market Attractiveness Analysis: End-use
6. Global Molecular Diagnostics Market Outlook: Region
6.1. Key Highlights
6.2. Historical Market Size (US$ Bn) Analysis by Region, 2019-2024
6.3. Current Market Size (US$ Bn) Forecast, by Region, 2025-2032
6.3.1. North America
6.3.2. Europe
6.3.3. East Asia
6.3.4. South Asia & Oceania
6.3.5. Latin America
6.3.6. Middle East & Africa
6.4. Market Attractiveness Analysis: Region
7. North America Molecular Diagnostics Market Outlook: Historical (2019-2024) and Forecast (2025-2032)
7.1. Key Highlights
7.2. Pricing Analysis
7.3. North America Market Size (US$ Bn) Forecast, by Country, 2025-2032
7.3.1. U.S.
7.3.2. Canada
7.4. North America Market Size (US$ Bn) Forecast, by Product Type, 2025-2032
7.4.1. Instruments
7.4.1.1. Polymerase Chain Reaction (PCR) Systems
7.4.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
7.4.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
7.4.1.4. Microarrays
7.4.2. Reagent
7.4.2.1. Antibodies
7.4.2.2. DNA Template
7.4.2.3. DNA Polymerase
7.4.2.4. Oligonucleotide Primers
7.4.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
7.4.2.6. Buffer
7.4.3. Assay Kits
7.4.4. Consumables
7.5. North America Market Size (US$ Bn) Forecast, by Disease Area, 2025-2032
7.5.1. Infectious Disease
7.5.2. Diabetes
7.5.3. Cardiology
7.5.4. Oncology
7.5.5. Nephrology
7.5.6. Autoimmune Disease
7.5.7. Dermatology
7.5.8. Wound Care
7.5.9. Others
7.6. North America Market Size (US$ Bn) Forecast, by End-use, 2025-2032
7.6.1. Hospitals & Clinics
7.6.2. Diagnostics Laboratories
7.6.3. Academic and Research Institutes
7.6.4. Biopharmaceutical Companies
8. Europe Molecular Diagnostics Market Outlook: Historical (2019-2024) and Forecast (2025-2032)
8.1. Key Highlights
8.2. Pricing Analysis
8.3. Europe Market Size (US$ Bn) Forecast, by Country, 2025-2032
8.3.1. Germany
8.3.2. Italy
8.3.3. France
8.3.4. U.K.
8.3.5. Spain
8.3.6. Russia
8.3.7. Rest of Europe
8.4. Europe Market Size (US$ Bn) Forecast, by Product Type, 2025-2032
8.4.1. Instruments
8.4.1.1. Polymerase Chain Reaction (PCR) Systems
8.4.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
8.4.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
8.4.1.4. Microarrays
8.4.2. Reagent
8.4.2.1. Antibodies
8.4.2.2. DNA Template
8.4.2.3. DNA Polymerase
8.4.2.4. Oligonucleotide Primers
8.4.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
8.4.2.6. Buffer
8.4.3. Assay Kits
8.4.4. Consumables
8.5. Europe Market Size (US$ Bn) Forecast, by Disease Area, 2025-2032
8.5.1. Infectious Disease
8.5.2. Diabetes
8.5.3. Cardiology
8.5.4. Oncology
8.5.5. Nephrology
8.5.6. Autoimmune Disease
8.5.7. Dermatology
8.5.8. Wound Care
8.5.9. Others
8.6. Europe Market Size (US$ Bn) Forecast, by End-use, 2025-2032
8.6.1. Hospitals & Clinics
8.6.2. Diagnostics Laboratories
8.6.3. Academic and Research Institutes
8.6.4. Biopharmaceutical Companies
9. East Asia Molecular Diagnostics Market Outlook: Historical (2019-2024) and Forecast (2025-2032)
9.1. Key Highlights
9.2. Pricing Analysis
9.3. East Asia Market Size (US$ Bn) Forecast, by Country, 2025-2032
9.3.1. China
9.3.2. Japan
9.3.3. South Korea
9.4. East Asia Market Size (US$ Bn) Forecast, by Product Type, 2025-2032
9.4.1. Instruments
9.4.1.1. Polymerase Chain Reaction (PCR) Systems
9.4.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
9.4.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
9.4.1.4. Microarrays
9.4.2. Reagent
9.4.2.1. Antibodies
9.4.2.2. DNA Template
9.4.2.3. DNA Polymerase
9.4.2.4. Oligonucleotide Primers
9.4.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
9.4.2.6. Buffer
9.4.3. Assay Kits
9.4.4. Consumables
9.5. East Asia Market Size (US$ Bn) Forecast, by Disease Area, 2025-2032
9.5.1. Infectious Disease
9.5.2. Diabetes
9.5.3. Cardiology
9.5.4. Oncology
9.5.5. Nephrology
9.5.6. Autoimmune Disease
9.5.7. Dermatology
9.5.8. Wound Care
9.5.9. Others
9.6. East Asia Market Size (US$ Bn) Forecast, by End-use, 2025-2032
9.6.1. Hospitals & Clinics
9.6.2. Diagnostics Laboratories
9.6.3. Academic and Research Institutes
9.6.4. Biopharmaceutical Companies
10. South Asia & Oceania Molecular Diagnostics Market Outlook: Historical (2019-2024) and Forecast (2025-2032)
10.1. Key Highlights
10.2. Pricing Analysis
10.3. South Asia & Oceania Market Size (US$ Bn) Forecast, by Country, 2025-2032
10.3.1. India
10.3.2. Southeast Asia
10.3.3. ANZ
10.3.4. Rest of SAO
10.4. South Asia & Oceania Market Size (US$ Bn) Forecast, by Product Type, 2025-2032
10.4.1. Instruments
10.4.1.1. Polymerase Chain Reaction (PCR) Systems
10.4.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
10.4.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
10.4.1.4. Microarrays
10.4.2. Reagent
10.4.2.1. Antibodies
10.4.2.2. DNA Template
10.4.2.3. DNA Polymerase
10.4.2.4. Oligonucleotide Primers
10.4.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
10.4.2.6. Buffer
10.4.3. Assay Kits
10.4.4. Consumables
10.5. South Asia & Oceania Market Size (US$ Bn) Forecast, by Disease Area, 2025-2032
10.5.1. Infectious Disease
10.5.2. Diabetes
10.5.3. Cardiology
10.5.4. Oncology
10.5.5. Nephrology
10.5.6. Autoimmune Disease
10.5.7. Dermatology
10.5.8. Wound Care
10.5.9. Others
10.6. South Asia & Oceania Market Size (US$ Bn) Forecast, by End-use, 2025-2032
10.6.1. Hospitals & Clinics
10.6.2. Diagnostics Laboratories
10.6.3. Academic and Research Institutes
10.6.4. Biopharmaceutical Companies
11. Latin America Molecular Diagnostics Market Outlook: Historical (2019-2024) and Forecast (2025-2032)
11.1. Key Highlights
11.2. Pricing Analysis
11.3. Latin America Market Size (US$ Bn) Forecast, by Country, 2025-2032
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Rest of LATAM
11.4. Latin America Market Size (US$ Bn) Forecast, by Product Type, 2025-2032
11.4.1. Instruments
11.4.1.1. Polymerase Chain Reaction (PCR) Systems
11.4.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
11.4.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
11.4.1.4. Microarrays
11.4.2. Reagent
11.4.2.1. Antibodies
11.4.2.2. DNA Template
11.4.2.3. DNA Polymerase
11.4.2.4. Oligonucleotide Primers
11.4.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
11.4.2.6. Buffer
11.4.3. Assay Kits
11.4.4. Consumables
11.5. Latin America Market Size (US$ Bn) Forecast, by Disease Area, 2025-2032
11.5.1. Infectious Disease
11.5.2. Diabetes
11.5.3. Cardiology
11.5.4. Oncology
11.5.5. Nephrology
11.5.6. Autoimmune Disease
11.5.7. Dermatology
11.5.8. Wound Care
11.5.9. Others
11.6. Latin America Market Size (US$ Bn) Forecast, by End-use, 2025-2032
11.6.1. Hospitals & Clinics
11.6.2. Diagnostics Laboratories
11.6.3. Academic and Research Institutes
11.6.4. Biopharmaceutical Companies
12. Middle East & Africa Molecular Diagnostics Market Outlook: Historical (2019-2024) and Forecast (2025-2032)
12.1. Key Highlights
12.2. Pricing Analysis
12.3. Middle East & Africa Market Size (US$ Bn) Forecast, by Country, 2025-2032
12.3.1. GCC Countries
12.3.2. South Africa
12.3.3. Northern Africa
12.3.4. Rest of MEA
12.4. Middle East & Africa Market Size (US$ Bn) Forecast, by Product Type, 2025-2032
12.4.1. Instruments
12.4.1.1. Polymerase Chain Reaction (PCR) Systems
12.4.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
12.4.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
12.4.1.4. Microarrays
12.4.2. Reagent
12.4.2.1. Antibodies
12.4.2.2. DNA Template
12.4.2.3. DNA Polymerase
12.4.2.4. Oligonucleotide Primers
12.4.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
12.4.2.6. Buffer
12.4.3. Assay Kits
12.4.4. Consumables
12.5. Middle East & Africa Market Size (US$ Bn) Forecast, by Disease Area, 2025-2032
12.5.1. Infectious Disease
12.5.2. Diabetes
12.5.3. Cardiology
12.5.4. Oncology
12.5.5. Nephrology
12.5.6. Autoimmune Disease
12.5.7. Dermatology
12.5.8. Wound Care
12.5.9. Others
12.6. Middle East & Africa Market Size (US$ Bn) Forecast, by End-use, 2025-2032
12.6.1. Hospitals & Clinics
12.6.2. Diagnostics Laboratories
12.6.3. Academic and Research Institutes
12.6.4. Biopharmaceutical Companies
13. Competition Landscape
13.1. Market Share Analysis, 2025
13.2. Market Structure
13.2.1. Competition Intensity Mapping
13.2.2. Competition Dashboard
13.3. Company Profiles
13.3.1. Becton, Dickinson and Company
13.3.1.1. Company Overview
13.3.1.2. Product Portfolio/Offerings
13.3.1.3. Key Financials
13.3.1.4. SWOT Analysis
13.3.1.5. Company Strategy and Key Developments
13.3.2. Bio-Rad Laboratories In
13.3.3. Merck KgaA
13.3.4. Thermo Fisher Scientific Inc
13.3.5. Agilent Technologies, Inc.
13.3.6. F. Hoffman - La Roche Ltd.
13.3.7. Illumina, Inc.
13.3.8. Qiagen N.V.
13.3.9. Hologic Inc.
13.3.10. Siemens Healthineers AG
13.3.11. Seegene, Inc.
13.3.12. DiaSorin S.p.A
13.3.13. Grifols, S.A.
13.3.14. bioMerieux
13.3.15. QuidelOrtho Corporation
14. Appendix
14.1. Research Methodology
14.2. Research Assumptions
14.3. Acronyms and Abbreviations